{"id":"binimetinib-oral-tablet","safety":{"commonSideEffects":[{"rate":"44%","effect":"Diarrhea"},{"rate":"34%","effect":"Nausea"},{"rate":"29%","effect":"Vomiting"},{"rate":"27%","effect":"Fatigue"},{"rate":"24%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Binimetinib is a small molecule inhibitor of MEK1 and MEK2, enzymes that are part of the MAPK/ERK signaling pathway. This pathway is involved in cell division and growth, and is often dysregulated in cancer cells.","oneSentence":"MEK1/2 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:06.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT04074096","phase":"PHASE2","title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2022-09-05","conditions":"Malignant Melanoma, BRAF V600 Mutation, Brain Metastases","enrollment":10},{"nctId":"NCT03915951","phase":"PHASE2","title":"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-04","conditions":"Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT05203172","phase":"PHASE4","title":"The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":46},{"nctId":"NCT01909453","phase":"PHASE3","title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-12","conditions":"Melanoma","enrollment":921},{"nctId":"NCT05286788","phase":"PHASE2","title":"MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2023-04-10","conditions":"Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma","enrollment":38},{"nctId":"NCT04585815","phase":"PHASE1, PHASE2","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT05195632","phase":"PHASE2","title":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2022-06-02","conditions":"Non-Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT04892017","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2021-06-15","conditions":"Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":144},{"nctId":"NCT02185690","phase":"PHASE1","title":"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2017-03-07","conditions":"Lungcancer","enrollment":13},{"nctId":"NCT03898908","phase":"PHASE2","title":"Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain","status":"COMPLETED","sponsor":"Grupo Español Multidisciplinar de Melanoma","startDate":"2019-07-18","conditions":"Metastatic Melanoma, Brain Metastases","enrollment":48},{"nctId":"NCT03839342","phase":"PHASE2","title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-06-07","conditions":"Solid Tumor","enrollment":26},{"nctId":"NCT03374254","phase":"PHASE1","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-16","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06207656","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2024-04-16","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT05810740","phase":"PHASE1","title":"Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2022-08-31","conditions":"Melanoma, BRAF V600 Mutation, Unresectable Melanoma","enrollment":37},{"nctId":"NCT05270044","phase":"PHASE3","title":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2022-05-02","conditions":"Melanoma","enrollment":815},{"nctId":"NCT05370807","phase":"PHASE2","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-10-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":48},{"nctId":"NCT03878719","phase":"PHASE1","title":"Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-08-03","conditions":"Melanoma","enrollment":1},{"nctId":"NCT05103891","phase":"PHASE1","title":"Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations","status":"UNKNOWN","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-03","conditions":"Melanoma, BRAF V600 Mutation, Unresectable Melanoma","enrollment":14},{"nctId":"NCT03158103","phase":"PHASE1","title":"A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-04-15","conditions":"Gastrointestinal Stromal Tumor (GIST)","enrollment":3},{"nctId":"NCT01927341","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-11-19","conditions":"Metastatic Colorectal Cancer","enrollment":53},{"nctId":"NCT01469130","phase":"PHASE1","title":"A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2011-11","conditions":"Advanced Solid Tumor","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mektovi"],"phase":"phase_2","status":"active","brandName":"Binimetinib Oral Tablet","genericName":"Binimetinib Oral Tablet","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEK1/2 inhibitor Used for Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}